Testosterone Lawsuits Consolidated into Multidistrict Litigation in Northern District of Illinois, Reports Baron and Budd

Transfer Order Consolidates 49 Testosterone Lawsuits Involving Several Different Manufacturers

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This

DALLAS, TX (PRWEB) June 14, 2014

The United States Judicial Panel on Multidistrict Litigation (MDL) issued a Transfer Order on June 6, 2014 creating an MDL for 49 testosterone lawsuits in the U.S. District Court, Northern District of Illinois, reports the national law firm of Baron and Budd. Plaintiffs in the lawsuits allege drugs such as AndroGel, AndroDerm, Axiron, Foresta, Testim and others caused serious – and sometimes fatal – cardiovascular problems in men. There are dozens of other cases pending in federal courts across the nation that may eventually be transferred as well. (In re: Testosterone Replacement Therapy Product Liability Litigation – MDL No. 2545.)

The purpose of creating an MDL is to facilitate faster progression of a large number of lawsuits that have certain allegations of fact in common. Creation of an MDL is designed to eliminate inconsistent court rulings among these cases, as well as expensive and unnecessary duplication of discovery. All of the lawsuits that were transferred to the Northern District of Illinois allege that testosterone replacement therapies caused certain damaging cardiovascular side effects. According to the June 6 Order, plaintiffs predict the number of lawsuits associated with testosterone therapy side effects could eventually be in the thousands.
(http://www.jpml.uscourts.gov/sites/jpml/files/MDL-2545-Initial_Transfer-05-14.pdf)

In addition, the Order states that the Panel granted a request that an industry-wide proceeding be established because more than one drug is involved in many of the testosterone lawsuits being filed. Because the majority of claims were pending in the Northern District of Illinois, that court was chosen for the MDL.

Testosterone therapy drugs are typically used to treat a condition known as hypogonadism, or low testosterone, due to an underlying medical disorder. Disorders can include problems involving the hypothalamus gland as well as the effects of chemotherapy. On January 31, 2014, the U.S. Food and Drug Administration (FDA) announced that it was reviewing the safety of testosterone therapy drugs after studies revealed the increased potential of strokes and heart attacks in men who took the drugs.
(http://www.fda.gov/Drugs/DrugSafety/ucm383904.htm)

“This is yet another sign that testosterone lawsuits are progressing,” said Stephen Blackburn, attorney at the national law firm Baron and Budd. “We will continue to work tirelessly on behalf of men who have suffered harm after using testosterone therapy drugs.”

If you or the man in your life has experienced cardiovascular problems after taking testosterone therapy drugs, the national law firm of Baron and Budd may be of assistance. Call 1-866-472-9108 or visit our website at http://baronandbudd.com/areas-of-practice/pharmaceuticals/testosterone-therapy/ to learn more.

ABOUT BARON AND BUDD

The law firm of Baron and Budd, with offices in Dallas, Baton Rouge, Austin and Los Angeles, is a nationally recognized law firm with over 35 years of “Protecting What’s Right” for people, communities and businesses harmed by negligence. Baron & Budd’s size and resources enable the firm to take on large and complex cases. The firm represents individuals, governmental and business entities in areas as diverse as water contamination, Gulf oil spill, Qui Tam, California Proposition 65 violations, unsafe drugs and medical devices, Chinese drywall, deceptive advertising, consumer financial fraud, securities fraud and asbestos cancers such as mesothelioma.


Contact